Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alnylam's Liver Cancer RNAi Program Enters The Clinic

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Alnylam Pharmaceuticals's ALN-VSP RNA interference program has begun clinical trials in patients with advanced liver cancers, the Cambridge-MA.-based biotech said April 3

You may also be interested in...



Alnylam Finds Partner For Liver Cancer Program In China’s Ascletis

U.S.-China hybrid Ascletis is in-licensing rights to Phase II-ready RNA-interference program ALN-VSP from Alnylam with an eye on developing a groundbreaking therapy for an underserved indication that hits especially hard in China.

Ascletis Strategy Begins To Reach Fruition In Deal With Alnylam For HCC Candidate

U.S.-China hybrid Ascletis is in-licensing rights to Phase II-ready RNA-interference program ALN-VSP from Alnylam with an eye on developing a groundbreaking therapy for an underserved indication that hits especially hard in China.

Alnylam Set To Bring 3rd Program Into Clinic; Continue Progress Of Other Two

Alnylam plans to file an IND at FDA by the end of this year for a drug candidate to treat transthyretin-mediated amyloidosis (ATTR), with a goal of beginning Phase I study early next year, the biotech reported during an investor research and development presentation Nov. 12 (see chart: "1Alnylam's Aggressive Business Development Program Has Yielded Results")

Related Content

Topics

UsernamePublicRestriction

Register

PS004111

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel